Back to Journals » OncoTargets and Therapy » Volume 12

miR-124, a potential therapeutic target in colorectal cancer

Authors Qin Z, Liu X

Received 8 July 2018

Accepted for publication 19 September 2018

Published 22 January 2019 Volume 2019:12 Pages 749—751

DOI https://doi.org/10.2147/OTT.S179501

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly


Zhen Qin,1,2 Xia Liu1,2

1Department of Clinical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China; 2Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Abstract: Recently, miR-124 has been regarded as a critical modulator of colorectal cancer. We here summarize the studies on the role and mechanism of miR-124 in colorectal cancer. They indicate that miR-124 is methylated during carcinogenesis and functions as a tumor-suppressor in colorectal cancer. miR-124 might serve as a potential diagnostic biomarker and therapeutic target in colorectal cancer in the foreseeable future.

Keywords: miR-124, colorectal cancer, biomarker, methylation, therapeutic target


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]